J&J suspends COVID-19 vaccine sales forecast

Johnson & & Johnson is suspending sales forecasts for its COVID-19 vaccine just a couple of months after saying the shot could generate as much as $3.5 billion this yearBy TOM MURPHY AP Health WriterApril 19, 2022, 11:40 AM – 2 minutes readShare to FacebookShare to TwitterEmail this articleJohnson & & Johnson is suspending sales forecasts for its COVID-19 vaccine just a few months after saying the shot might bring in as much as $3.5 billion this year.The health care giant said Tuesday that a global supply surplus and need unpredictability triggered the relocation, which will not impact the businesss operational earnings per share guidance.J&& Js one-shot vaccine brought in $457 million in international sales during the very first quarter, with most of that originating from outside the United States. The vaccine generated only $75 million in sales in the U.S., or about 25% less than what it phoned after debuting in last years first quarter.J&& J has stated it doesnt plan to profit from the vaccine. It said in January that it could bring in between $3 billion and $3.5 billion in sales this year, as nations continue to combat versions of the virus.The vaccine brought in $2.38 billion in sales last year.Vaccine alternatives from competing drugmakers Pfizer and Moderna have actually been much more commonly used so far in the United States, where total vaccine sales have actually slowed in recent weeks as the omicron surge of the virus started to ease.U.S. regulators also have stated that a lot of Americans should get the Pfizer or Moderna shots rather of J&Js variation due to an uncommon blood clotting problem connected to the shot.